N2038
Anti-NY-ESO-1 antibody, Mouse monoclonal
clone E978, purified from hybridoma cell culture
Synonym(s):
Anti-CTAG1, Anti-Cancer/Testis Antigen 1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
E978, monoclonal
form
buffered aqueous solution
mol wt
antigen ~23 kDa
species reactivity
human
packaging
antibody small pack of 25 μL
concentration
~1 mg/mL
technique(s)
immunohistochemistry: suitable
indirect ELISA: suitable
western blot: 1-2 μg/mL using SKMel-37 total cell extract
isotype
IgG1
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... CTAG1B(1485)
General description
Monoclonal Anti-NY-ESO-1 (mouse IgG1 isotype) is derived from the hybridoma E978 produced by the fusion of mouse myeloma cells (SP2/0) and splenocytes from BALB/c mice immunized with human recombinant NY-ESO-1. The NY-ESO-1, also known as cancer/testis antigen 1 is expressed in normal testis and to a much lower extent in placenta, ovary and uterus.
Immunogen
recombinant human NY-ESO-1.
Application
Monoclonal Anti-NY-ESO-1 antibody produced in mouse has been used in enzyme linked immunosorbent assays (ELISA), immunoblotting and immunohistochemistry.
Monoclonal Anti-NY-ESO-1 is used as a probe to determine the presence and roles of Cancer/Testis Antigen 1 in humoral immune responses and a variety of cancers.
Biochem/physiol Actions
Cancer/testis (CT) antigens are the protein products of genes that are activated in a wide variety of tumors and can elicit autologous cellular and humoral immune responses. Their normal expression is restricted to male germ cells in the testis and they are not expressed in adult somatic tissues. Therefore, CT antigens are promising candidates for cancer immunotherapy. Approximately 20 CT antigens or antigen families have been identified to date. NY-ESO-1 is a CT protein to which cell-mediated immune response has been demonstrated. It is highly expressed in various types of cancers. For example, patients with melanoma contain tumor-infiltrating lymphocytes cells (TILs) that recognized NY-ESO-1 protein. The expression of genes encoding CT antigens was examined in sporadic medullary thyroid carcinoma. The expression of NY-ESO-1 was found in 65 percent of the samples and correlated with tumor recurrence in primary MTC tumors. Furthermore, high frequency of expression was found in breast cancer especially in benign lesions and in multiple myeloma. Due to its wide expression in different cancers, NY-ESO-1 protein was used as a vaccine in cancer patients.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Elizabeth Shurell et al.
Oncotarget, 7(45), 72860-72867 (2016-09-23)
Immunotherapy targeting cancer-testis antigen NY-ESO-1 shows promise for tumors with poor response to chemoradiation. Malignant peripheral nerve sheath tumors (MPNSTs) and liposarcomas (LPS) are chemoresistant and have few effective treatment options. Materials Methods: Using a comprehensive tissue microarray (TMA) of
Shanshan W Howland et al.
Journal of immunotherapy (Hagerstown, Md. : 1997), 31(7), 607-619 (2008-07-05)
Saccharomyces cerevisiae stimulates dendritic cells (DCs) and represents a promising candidate for cancer vaccine development. Effective cross-presentation of antigen delivered to DCs is necessary for successful induction of cellular immunity. Here, we present a yeast-based vaccine approach that is independent
Iris Scherwitzl et al.
Molecular therapy oncolytics, 9, 51-63 (2018-07-11)
Oncolytic viruses represent a promising form of cancer immunotherapy. We investigated the potential of Sindbis virus (SV) for the treatment of solid tumors expressing the human cancer testis antigen NYESO-1. NYESO-1 is an immunogenic antigen frequently expressed in numerous cancers
Shinichi Kageyama et al.
Journal of translational medicine, 11, 246-246 (2013-10-08)
Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated the safety, immune responses and clinical outcomes of patients who received the CHP-NY-ESO-1 complex vaccine, Drug code: IMF-001. Patients with advanced/metastatic esophageal cancer were enrolled
Shugo Ueda et al.
Oncotarget, 9(89), 35997-36011 (2018-12-14)
MAGE-A4 antigen is a cancer-testis antigen that is frequently expressed in tumor tissues. Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated the safety, immune responses and clinical outcomes of patients who received a
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service